Cambium Bio (ASX:CMB) Short Interest


ASX:CMB Cambium Bio Ltd ASX:CMB
34 GF Score
Price A$0.42
! 4 Warning Signs
View Full Analysis

What is Cambium Bio Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ASX:CMB vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Cambium Bio's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Short Interest distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Short Interest falls into.


ASX:CMB
34GF Score
Cambium Bio Ltd ASX:CMB
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
34GF Score

Get the complete analysis for ASX:CMB

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42
Price